Quarterly report pursuant to Section 13 or 15(d)

Investments - Narrative (Details)

v3.20.2
Investments - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 30, 2017
Apr. 30, 2017
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]              
Total assets of equity method investees     $ 2,371,291   $ 2,371,291   $ 2,309,272
Total (liabilities) of equity method investees     (747,521)   (747,521)   $ (694,513)
Net losses of equity method investees     (23,717) $ 62,007 1,712 $ 202,575  
Market value     6,200   6,200    
Equity Method Investment, Nonconsolidated Investee or Group of Investees              
Schedule of Equity Method Investments [Line Items]              
Total assets of equity method investees     89,200   89,200    
Total (liabilities) of equity method investees     $ (37,000)   (37,000)    
Net losses of equity method investees         $ 51,200    
Pharmsynthez              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     9.00%   9.00%    
Cocrystal              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     5.00%   5.00%    
Number of shares into which warrants may be converted (in shares)     33,000   33,000    
Additional investment in equity method investment   $ 1,000          
Non-Invasive Monitoring Systems, Inc.              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     1.00%   1.00%    
Neovasc              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     2.00%   2.00%    
Additional investment in equity method investment $ 3,000            
InCellDx, Inc              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     29.00%   29.00%    
Number of shares into which warrants may be converted (in shares)     700,000   700,000    
BioCardia, Inc.              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     2.00%   2.00%    
Ownership percentage     2.00%   2.00%    
Number of shares into which warrants may be converted (in shares)     47,000   47,000    
Investment options, vested (in shares)     37,000   37,000    
Xenetic Biosciences, Inc.              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     3.00%   3.00%    
Number of shares into which warrants may be converted (in shares)     40,000   40,000    
Phio Pharmaceuticals              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage     0.01%   0.01%    
Number of shares into which warrants may be converted (in shares)     404   404    
VBI Vaccines Inc              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage     1.00%   1.00%    
ChromaDex              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage     0.10%   0.10%    
MabVax Therapeutics Holdings, Inc.              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage     1.00%   1.00%    
Eloxx Pharmaceuticals              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage     3.00%   3.00%    
Detect Genomix | Variable Interest Entity, Not Primary Beneficiary              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     49.00%   49.00%    
Additional investment in equity method investment         $ 245    
Zebra | Variable Interest Entity, Not Primary Beneficiary              
Schedule of Equity Method Investments [Line Items]              
Ownership percentage, equity method     29.00%   29.00%    
Series A Preferred Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary              
Schedule of Equity Method Investments [Line Items]              
Investment owned (in shares)     1,260,000   1,260,000    
Restricted Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary              
Schedule of Equity Method Investments [Line Items]              
Shares received as a gift (in shares)         900,000